Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

23-08-2022 | Gastric Cancer | ASO Author Reflections

ASO Author Reflections: Predicting Very Early Recurrence After Resection of Gastric Cancer

Authors: Gaya Spolverato, MD, Giulia Capelli, MD, Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

The incidence of recurrence among patients who undergo curative-intent resection of gastric cancer (GC) can be as high as 30–50%, which can impact long-term survival.1 Currently, surgical resection with perioperative chemotherapy represents the gold standard for treatment of localized disease.2 Long-term outcomes following surgery often depend on patient-related and tumor-related variables. While several prognostic models have been proposed,3 the incidence and risk factors associated with very early recurrence (VER), defined as a recurrence occurring within 6 months of surgery, have not been investigated. We sought to characterize the incidence and pattern of VER among patients with GC undergoing curative-intent surgery, as well as develop a prognostic nomogram to predict VER and recurrence within 1 year of surgery. …
Literature
1.
Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219(4):664–75.CrossRefPubMed
2.
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.CrossRefPubMed
3.
Spolverato G, Capelli G, Lorenzoni G, et al. Development of a prognostic nomogram and nomogram software application tool to predict overall survival and disease-free survival after curative-intent gastrectomy for gastric cancer. Ann Surg Oncol. 2022;29(2):1220–9.CrossRefPubMed
4.
Metadata
Title
ASO Author Reflections: Predicting Very Early Recurrence After Resection of Gastric Cancer
Authors
Gaya Spolverato, MD
Giulia Capelli, MD
Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA
Publication date
23-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12471-7

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

Correction

Correction: Encapsulated Angioinvasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion

Thoracic Oncology

Does Pretreatment Platelet Distribution Width Predict Prognosis in Esophageal Cancer?

Pediatric Oncology

Reply to: Letter to the Editor: Reflection on “Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma”

ASO Research Letter

Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

Melanoma

Educational Review: Neoadjuvant Approaches to Melanoma

Peritoneal Surface Malignancy

Natural History and Management of Small-Bowel Obstruction in Patients After Cytoreductive Surgery and Intraperitoneal Chemotherapy